Leitat projects €48M in 2023 revenue, with 20% from R&D. Its health division, founded in 2009, specializes in therapies and health predictors, focusing on personalized medicine and organoids. Collaborations include a vaccine with Ipra and a 70%-effective muscle injury predictor for FC Barcelona. Leitat expects 5-7% annual growth, emphasizing organic team expansion.
